In today’s recent session, 1.74 million shares of the Akebia Therapeutics Inc (NASDAQ:AKBA) have been traded, and its beta is 0.82. Most recently the company’s share price was $2.07, and it changed around -$0.06 or -2.87% from the last close, which brings the market valuation of the company to $540.43M. AKBA at last check was trading at a discount to its 52-week high of $2.89, offering almost -39.61% off that amount. The share price’s 52-week low was $0.80, which indicates that the recent value has risen by an impressive 61.35% since then. We note from Akebia Therapeutics Inc’s average daily trading volume that its 10-day average is 8.51 million shares, with the 3-month average coming to 3.22 million.
Akebia Therapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended AKBA as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Akebia Therapeutics Inc is expected to report earnings per share of -0.04 for the current quarter.
Akebia Therapeutics Inc (NASDAQ:AKBA) trade information
Instantly AKBA has been showing red trend so far today with a performance of -2.87% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.89 on recent trading dayincreased the stock’s daily price by 28.37%. The company’s shares are currently up 8.88% year-to-date, but still down -13.80% over the last five days. On the other hand, Akebia Therapeutics Inc (NASDAQ:AKBA) is 14.93% up in the 30-day period. We can see from the shorts that 14.88 million shares have been sold at a short interest cover period of 7.64 day(s).
The consensus price target as assigned by Wall Street analysts is $6.5, which translates to bulls needing to increase their stock price by 68.15% from its current value. Analyst projections state that AKBA is forecast to be at a low of $6 and a high of $7.
Akebia Therapeutics Inc (AKBA) estimates and forecasts
The year-over-year growth rate is expected to be 20.99%, up from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 44.38M in revenue for the current quarter. 3 analysts expect Akebia Therapeutics Inc to make 44.13M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 32.61M and 43.65M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 36.09%. Forecasts for the next quarter put sales growth at 1.12%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 32.58%.
Akebia Therapeutics Inc (NASDAQ:AKBA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.21% of Akebia Therapeutics Inc shares, and 27.33% of them are in the hands of institutional investors. The stock currently has a share float of 28.53%. Akebia Therapeutics Inc stock is held by 154.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 5.6786% of the shares, which is about 11.64 million shares worth $11.87 million.
VANGUARD GROUP INC, with 4.526% or 9.28 million shares worth $9.46 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024. The former held 5.95 shares worth $12.34 million, making up 2.52% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 5.72 shares worth around $11.87 million, which represents about 2.42% of the total shares outstanding.
